Related Experiment Videos
Cloned antigens and antiidiotypes
D Herlyn1, R Somasundaram, J Zaloudik
1Wistar Institute, Philadelphia, PA 19104, USA.
Hybridoma
|April 1, 1995
Summary
Recombinant colorectal cancer (CRC) antigen CO17-1A/GA733 shows promise as a vaccine. Preclinical studies indicate it elicits stronger immune responses than anti-idiotypic antibodies, suggesting potential for CRC patient treatment.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Monoclonal and polyclonal anti-idiotypic antibodies mimicking colorectal carcinoma (CRC) antigen CO17-1A/GA733 have induced immunity in CRC patients.
- Observed immune responses may correlate with clinical benefits in some patients.
Purpose of the Study:
- To evaluate the immunogenicity of molecularly cloned and expressed CO17-1A/GA733 antigen.
- To compare the immune responses elicited by recombinant antigen versus anti-idiotypic antibodies.
Main Methods:
- Molecular cloning and expression of CO17-1A/GA733 antigen in baculo-, adeno-, and vaccinia viruses.
- Preclinical studies assessing humoral and cellular immunity in response to recombinant antigen.
- Comparison of antibody titers induced by recombinant antigen and anti-idiotypic antibodies.
Main Results:
- Recombinant CO17-1A/GA733 antigen preparations elicited specific humoral immunity (cytotoxic antibodies) and cellular immunity (DTH-reactive and proliferative T cells).
- Antibody titers in animals were significantly higher when induced by recombinant antigen compared to anti-idiotypes.
- The recombinant antigen demonstrated potential for inducing robust immune responses.
Conclusions:
- The molecularly cloned and expressed CO17-1A/GA733 antigen is a potent immunogen.
- Recombinant antigen preparations show superior immunogenicity compared to anti-idiotypic antibodies.
- The recombinant antigen holds significant potential as a vaccine candidate for colorectal cancer patients.